Erratum: Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (Blood (2018) 131:14 (1522-1531) DOI: 10.1182/blood-2017-08-798322);Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Blood

Volumn 131, Issue 14, 2018, Pages 1522-1531

  Gökbuget, Nicola ⁿ   Dombret, Hervé ^a   Bonifacio, Massimiliano ^b   Reichle, Albrecht ^c   Graux, Carlos ^d   Faul, Christoph ^e   Diedrich, Helmut ^f   Topp, Max S ^g   Brüggemann, Monika ^h   Horst, Heinz August ^h   Havelange, Violaine ⁱ   Stieglmaier, Julia ^j   Wessels, Hendrik ^j   Haddad, Vincent ^k   Benjamin, Jonathan E ^l   Zugmaier, Gerhard ^j   Nagorsen, Dirk ^l   Bargou, Ralf C ^m  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j Amgen Research GmbH   (Germany)

^k AMGEN LTD   (United Kingdom)

^l AMGEN INC   (United States)

^m Uniklinikum Würzburg   (Germany)

ⁿ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; CORTICOSTEROID; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVERSE DRUG REACTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; APHASIA; ARTICLE; B CELL LEUKEMIA; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CONFUSION; CONTINUOUS INFUSION; CYTOGENETICS; CYTOKINE RELEASE SYNDROME; DISORIENTATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EUROPE; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEADACHE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RUSSIAN FEDERATION; SEIZURE; SUBDURAL HEMATOMA; T-CELL GENE REARRANGEMENT; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREMOR; VERY ELDERLY; ADOLESCENT; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BISPECIFIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SURVIVAL RATE;

EID: 85047575618     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood.2019001109     Document Type: Erratum

References (37)

1. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6): 1013-1034.
2. van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996-4009.
3. Brüggemann M, Raff T, Flohr T, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3): 1116-1123.
4. Gökbuget N, Kneba M, Raff T, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9): 1868-1876.
5. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD study. Br J Haematol. 2008;142(2): 227-237.
6. Raff T, Gökbuget N, Lüschen S, et al; GMALL Study Group. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3): 910-915.
7. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18): 4153-4162.
8. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142): 1731-1738.
9. Borowitz MJ, Devidas M, Hunger SP, et al; Children’s Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477-5485.
10. Brüggemann M, Gökbuget N, Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39(1):47-57.
11. Dhédin N, Huynh A, Maury S, et al; GRAALL group. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015; 125(16):2486-2496, quiz 2586.
12. Van der Velden VH, Corral L, Valsecchi MG, et al; Interfant-99 Study Group. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009;23(6):1073-1079.
13. Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
14. Beldjord K, Chevret S, Asnafi V, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24): 3739-3749.
15. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(5):532-543.
16. Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92(5):612-618.
17. Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014(1):244-249.
18. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974-977.
19. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098-1107.
20. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.
21. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185-5187.
22. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29(18):2493-2498.
23. Brüggemann M, Schrauder A, Raff T, et al; International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24(3): 521-535.
24. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66.
25. Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, et al; Study Group for Adult ALL of the European Leukemia Net. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant. 2010;45(6): 1095-1101.
26. Choi S, Henderson MJ, Kwan E, et al. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood. 2007;110(2): 632-639.
27. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
28. Kranick S, Phan G, Kochenderfer JN, Rosenberg SA, Nath A. Aphasia as a complication of CD19-targeted chimeric antigen receptor immunotherapy. Neurology. 2014; 82(10 suppl 1):S52.006.
29. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-1517.
30. Parizel PM, Snoeck HW, van den Hauwe L, et al. Cerebral complications of murine monoclonal CD3 antibody (OKT3): CT and MR findings. AJNR Am J Neuroradiol. 1997; 18(10):1935-1938.
31. Pavlů J, Labopin M, Zoellner AK, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the Acute Leukemia Working Party of the EBMT. Cancer. 2017; 123(11):1965-1970.
32. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3): 366-374.
33. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4): 1827-1833.
34. Wolach O, Stevenson KE, Wadleigh M, et al. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016;91(8):793-799.
35. Mohty M, Labopin M, Volin L, et al; Acute Leukemia Working Party of EBMT. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22): 4439-4443.
36. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program. 2012;2012:35-42.
37. Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood. 2009; 114(16):3376-3381.